Results 41 to 50 of about 13,388,853 (301)
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus [PDF]
Diabetes & Metabolism Journal, 2016 Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antidiabetic agent for the treatment of type 2 diabetes mellitus. They increase endogenous levels of incretin hormones, which stimulate glucose-dependent insulin secretion, decrease ...
Sung-Ho Kim +3 more
doaj +1 more source
Arthritis Care &Research, EarlyView.Objective To investigate the association between rheumatoid arthritis (RA) and coronary artery calcium (CAC) prevalence, incidence, and progression over four years in adults without prior cardiovascular disease. Methods A case‐cohort study within the Brazilian Longitudinal Study of Adult Health (ELSA‐Brasil) included 585 participants (86 patients with ...
Patrícia Fonseca Estrada +7 more
wiley +1 more source
Sitagliptin: the world’s first DPP-4 inhibitor
Медицинский совет, 2019 The prevalence of T2D is steadily increasing annually, which resulted in an active search for a way to control the disease. The last decade has seen a rise in the number of new groups of glucose-lowering drugs, which not only proved effective in the ...
N. A. Petunina +4 more
doaj +1 more source
DPP-4 inhibitor dose selection according to manufacturer specifications: A contemporary experience from UK general practice [PDF]
, 2019 Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and saxagliptin, adjusted dosing specification from creatinine clearance to glomerular filtration rate, more typically reported in routine laboratory tests.
Tebboth, Abigail +5 more
core +1 more source
Advanced Science, EarlyView.CFP/PC@MnO2 hydrogel integrates ROS scavenging, oxygen delivery, oxidative stress reduction, immunomodulation, and photothermal antibacterial properties. The incorporation of PC@MnO2 NPs endows the hydrogel with multiple functional advantages tailored to the pathological microenvironment of diabetic wounds, including efficient ROS clearance, mitigation
Zhi Xu +9 more
wiley +1 more source
Trends in Adverse Event Reports of Dipeptidyl Peptidase-4 Inhibitor-Associated Pemphigoid in Japan
Drugs - Real World OutcomesBackground Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used as a first-line therapy for type 2 diabetes in Japan. Precautions of the package inserts for ethical drugs containing DPP-4 inhibitors were revised for pemphigoid between 2016 and 2018.
Akina Takami +4 more
doaj +1 more source
Late Onset Dipeptidyl Peptidase -4 Inhibitor Associated Seronegative Rheumatoid Arthritis
Journal of Nepal Health Research Council, 2021 Drug-induced arthritis is not an uncommon scenario. DPP-4 inhibitors could potentially cause adverse-events mediated by cytokine-induced inflammation leading to arthritis. The activity of the DPP-4 enzyme could be inversely related to the development of
Binit Vaidya +3 more
doaj +1 more source
Advanced Science, EarlyView.Magneto‐NIR‐II‐programmed NFSH nanozymes integrate magnetic blood–brain barrier (BBB) translocation, CD44 targeting, multimodal imaging, and cascade catalytic therapy for glioblastoma. Alternating magnetic fields and NIR‐II irradiation amplify ferroptosis, release H2S, suppress autophagic and mitophagic repair, and reshape the immune microenvironment ...
Ruocan Liu +7 more
wiley +1 more source
Diabetes, Metabolic Syndrome and Obesity, 2020 Takeshi Osonoi, Miyoko Saito, Naoya Koda, Satako Douguchi, Takako Nakano, Kensuke Ofuchi, Makoto Katoh Naka Kinen Clinic, Ibaraki, JapanCorrespondence: Makoto KatohNaka Kinen Clinic, 745-5 Nakadai, Naka-Shi, Ibaraki 311-0113, JapanTel +81-29-353-2800Fax +
Osonoi T +6 more
doaj
DPP-4 Inhibitors: The Seinfeld of Oral Antihyperglycemics
The Canadian Journal of Hospital Pharmacy, 2016 -
Arden R, Barry, Ricky D, Turgeon
openaire +3 more sources